Corporate | 10 May 2012 17:36
|
MPH Mittelständische Pharma Holding AG / Key word(s): Quarter Results/Development of Sales
MPH Mittelständische Pharma Holding AG: 1st Quarter 2012: +15.7% Sales Growth; EBIT Margin 7.6% In the first quarter of 2012, the MPH Group achieved a turnover of 40.66 million Euro (previous year: 35.14 million Euro) hence achieving an increase of 15.7% in comparison to the same period of the previous year. The earnings obtained before interest and tax (EBIT) were 3.09 million Euro and reached a margin of 7.6%. The earnings obtained before amortisation; interest and tax (EBITDA) were 3.19 million Euro and reached a margin of 7.87%.
The preliminary EBIT margin of the fiscal year 2011 was 7.3%.
The MPH Group does expect a stronger sales growth in the next quarters of fiscal year 2012. About the company MPH Mittelständische Pharma Holding AG: The Berlin based company MPH Mittelständische Pharma Holding AG has strategically concentrated its activities on growth segments in the pharmaceutical market. With pharmaceutical products based on patent-free and patent-protected active substances, which are made available through the MPH group in the therapeutic areas oncology, HIV, rheumatology, neurology and cardiovascular diseases, a contribution is made towards cost reduction in the healthcare sector. MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open Market) of the Frankfurt stock exchange
Key capital market data for MPH Mittelständische Pharma Holding AG:
Contact:
Tel.: +49 (0) 30 897 30 86 60
End of Corporate News 10.05.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| 169285 10.05.2012 |